Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2015

Publication date: Available online 24 April 2015 Source:Acta Haematologica Polonica Author(s): Anna Dmoszyńska , Adam Walter-Croneck , Lidia Usnarska-Zubkiewicz , Beata Stella-Hołowiecka , Jan Walewski , Grzegorz Charliński , Wiesław Wiktor Jędrzejczak , Elżbieta Wiater , Ewa Lech-Marańda , Dominik Dytfeld , Mieczysław Komarnicki , Krzysztof Jamroziak , Tadeusz Robak , Artur Jurczyszyn , Joanna Mańko , Aleksander Skotnicki , Sebastian Giebel , Iwona Hus , Ryszard Czepko , Janusz Meder , Bogdan Małkowski , Krzysztof Giannopoulos New drugs introduced in recent years to the therapy of multiple myeloma patients resulted in better responses and prolongation of overall survival. Therapeutic regimens based on bortezomib, thalidomide and lenalidomide are recommended to most patients in first line therapy which are accompanied with prolonged treatment composed of consolidation and maintenance as well as transplantation procedure offered to older, fit patients. Besides the concept of longer treatment, it is recommended to start therapy in some patients earlier, taking into consideration biomarkers of active disease. Also, in this article, we described therapeutic recommendation for Waldenström macroglobulinemia and other plasmocytic dyscrasias.
Source: Acta Haematologica Polonica - Category: Hematology Source Type: research